Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma

Jacob Schachter, Uriel Katz, Arie Mahrer, Dov Barak, Liat Ziegel Ben David, Jacob Nusbacher, Yehuda Shoenfeld

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review


We have previously reported studies performed both in vitro and in laboratory animals, as well as a case study in humans, suggesting that intravenous immunoglobulin (IVIG) may be beneficial in the treatment of malignancies, including metastatic melanoma. As part of a phase II open label trial, we have administered IVIG to nine patients with metastatic melanoma who had been heavily treated. In two of nine (22%) patients treated every 3 weeks with IVIG (1 g/kg body weight), the disease stabilized. One patient had stable disease for 8 months; the other for 3 months. No serious adverse events (AEs) attributable to IVIG were observed. We conclude that IVIG therapy may be useful for the treatment of metastatic melanoma. Furthermore, we suggest that the effects of IVIG therapy might be enhanced by its use as an adjuvant in patients without evidence of disease following surgery.

Original languageEnglish
Title of host publicationAutoimmunity, Part B Novel Applications of Basic Research
PublisherBlackwell Publishing Inc.
Number of pages10
ISBN (Print)1573317098, 9781573317092
StatePublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632


  • Adverse events
  • Cancer
  • IVIG
  • Intravenous immunoglobulin
  • Melanoma metastasis


Dive into the research topics of 'Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma'. Together they form a unique fingerprint.

Cite this